Japanese encephalitis virus, inactivated
As of the edition of 20 October 2026, Japanese encephalitis virus, inactivated is a vaccine component: marketed, first approved in 2009 (US); US protection ended in 2021.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Marketed; latest approval 2009
- Kind
- Vaccine component
- Brand name
- Ixiaro
- First approved
- 30 March 2009 (US)
- Approvals on record
- 1 in 1 region
- Holder of the most recent approval
- Valneva
- Registered trials
- 7, 1 stopped early
- Disease areas
- Infections; Nervous system
US protection
US protection ended in 2021.
US protection ended in 2021, computed as 12 years from the first US licence because FDA publishes no date for this product. The application that gives this date is held by Valneva. The date is computed, not published.
This is the US only, and it is not the date generics or biosimilars can enter.
The exact date and the listings behind it
In the product2 listings count towards this date. The exact date and each listing are in the product.
See the exact date and the 2 listings behind itRequest access. Nothing is shown until you do.
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase not stated | 1 | 1 | 0 | 0 |
| Phase 1 | 2 | 1 | 0 | 1 |
| Phase 2 | 2 | 1 | 0 | 0 |
| Phase 4 | 2 | 2 | 0 | 0 |
| All trials | 7 |